A Single-Dose Study of Denosumab in Patients With Various Degrees of Renal Impairment
暂无分享,去创建一个
G. Block | Edward Lee | D. Padhi | Liang Fang | Geoffrey A Block | Henry G Bone | Liang Fang | Edward Lee | Desmond Padhi | H. Bone
[1] S. Cummings,et al. Effects of denosumab on fracture and bone mineral density by level of kidney function , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] G. Scagliotti,et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Carducci,et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.
[4] J. S. San Martin,et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. , 2011, The Journal of clinical endocrinology and metabolism.
[5] Y. Fujiwara,et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Jacques P. Brown,et al. Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] Jacques P. Brown,et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[9] Jacques P. Brown,et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] P. Kerr,et al. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[11] S. Cummings,et al. Renal function and rate of hip bone loss in older men: the Osteoporotic Fractures in Men Study , 2008, Osteoporosis International.
[12] M. Perazella,et al. Bisphosphonate nephrotoxicity. , 2008, Kidney international.
[13] P. Miller,et al. Two‐Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] E. Barrett-Connor,et al. Measures of Renal Function, BMD, Bone Loss, and Osteoporotic Fracture in Older Adults: The Rancho Bernardo Study , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] P. Miller,et al. Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .
[16] P. Kostenuik. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. , 2005, Current opinion in pharmacology.
[17] Steven W. Martin,et al. A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] P. Kostenuik,et al. The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism , 2005, Calcified Tissue International.
[19] Colin R Dunstan,et al. A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] J. Beitz,et al. Renal failure with the use of zoledronic acid. , 2003, The New England journal of medicine.
[21] Ethan M Balk,et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] Kdoqi Disclaimer. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] M. Panteghini,et al. Evaluation of a Fully Automated Assay to Measure C-Telopeptide of Type I Collagen in Serum , 2000, Clinical chemistry and laboratory medicine.
[24] D. Lacey,et al. The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts , 1999, The Journal of cell biology.
[25] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[26] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Brasier,et al. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. , 1988, The American journal of medicine.
[28] M. H. Gault,et al. Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.